akari立克次體 IgG ELISA試劑盒

R. akari IgG ELISA Kit

廣州健侖生物科技有限公司

主要用途：用于檢測人血清中的akari立克次體IgG抗體

產品規(guī)格：96T/盒

主要產品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細小病毒等病原微生物的 IFA、MIF、ELISA試劑。

akari立克次體 IgG ELISA試劑盒

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

利用酵母和人類細胞，Smerdon，Mao和他們的研究團隊發(fā)現，正常的TCR修復過程有兩個關鍵的步驟，以及一種叫做H2B的染色質蛋白質在*步中起著至關重要的作用。
為了幫助修復酶能夠進入被大力保護的DNA中，H2B首先會解開一個較小的蛋白質的扣子，就像你在一頓豐富的大餐后放松你的皮帶一樣，這使得DNA鏈放松和分開。隨著鏈的打開，維修人員才有空間進來和清楚損傷區(qū)域。
這較小的蛋白質的解開，被稱為deubiquitylation。Smerdon和Mao說，這個過程使得DNA的修復效率更高，并且沒有它的修復是不可能的。
他們的發(fā)現作為進一步研究染色質中的DNA修復在很大程度上的未知領域的基礎。他們的目標是更好地了解這一過程在人類身上的工作機理。
基因療法
“即使在基本技術層面上，我也沒有忽視這項研究zui終對人體健康而言所能做的，” Smerdon說。
“其中一個正在開發(fā)的治療方法是靶向基因療法，”他說。“如果一個病人有一個特定的基因突變，這個療法會為他們提供一個正常的拷貝來試圖糾正變異基因。雖然它已在某些疾病已經成功地做到這一點，但它仍然被修復缺陷案例中研究。”
Mao推測，在未來，有DNA修復問題的人可能會吃一種可以提供修復酶活性的藥物，就可以達到治療的目的。但這個想法還沒有任何臨床試驗。
周圍神經損傷后的自身功能恢復往往有限，因此，生物工程神經移植物復合細胞外基質分子，生長因子,藥物學輔助，及細胞移植修復周圍神經損傷等都成為研究熱點。脂肪干細胞已被證實具有成脂肪，成骨，成軟骨 多種分化潛能，因其材料來源廣泛，取材容易，分化為神經元能力強，倫理學爭議少等優(yōu)點，使其成為神經導管上覆蓋的優(yōu)秀種子細胞。
英國曼徹斯特大學炎癥與修復研究所Blond McIndoe 實驗室主要研究GABA及其他神經遞質周圍神經系統及成體干細胞中的作用，他們發(fā)現，特異性抑制P2X7受體能夠拯救ATP誘發(fā)細胞死亡，這可能解決神經損傷處干細胞移植成活率低的問題。作者的研究可能為神經修復結合細胞療法和藥物干預的發(fā)展指出新的方向。相關研究觀點發(fā)表在《中國神經再生研究(英文版)》雜志2014年7月第14 期雜志上。

Using yeast and human cells, Smerdon, Mao and their team found two key steps in the normal TCR repair process, as well as a chromatin protein called H2B that plays a crucial role in the first step.
To help the repair enzyme get into well-protected DNA, H2B will first unbutton a smaller protein just as you relax your belt after a rich meal, which relaxes and separates the DNA strand . As the chain opens, maintenance personnel have room to come in and clear the damaged area.
The solution of this smaller protein is called deubiquitylation. Smerdon and Mao said that this process makes the DNA repair more efficient, and without its repair is impossible.
Their findings serve as a basis for furthering the largely unknown area of ??DNA repair in chromatin. Their goal is to better understand the working mechanism of this process on human beings.
Gene therapy
"Even at the basic technical level, I did not neglect what the research could ultimay do to human health," Smerdon said.
"One of the treatments that is being developed is targeted gene therapy," he said. "If a patient has a particular mutation, the therapy will provide them with a normal copy in an attempt to correct the variant gene.Although it has been successfully done in certain diseases, it is still being fixed in the case of defects the study."
Mao speculated that in the future, people with DNA repair problems may eat a drug that provides repair enzyme activity for therapeutic purposes. But this idea has not had any clinical trial yet.
Peripheral nerve injury after their own functional recovery is often limited, therefore, bioengineered nerve graft compound extracellular matrix molecules, growth factors, pharmacological assistance, and cell transplantation to repair peripheral nerve injury have become the research hotspot. Adipose-derived stem cells have been proven to have multiple adipogenic, osteogenic, and cartilage potential for differentiation because of their wide range of materials, ease of harvesting, strong ability to differentiate into neurons, and less ethical controversy that make them neurotransduction-covered Excellent seed cells.
The Blond McIndoe Laboratory at the Institute of Inflammation and Rehabilitation, University of Manchester, UK, has been investigating the role of GABA and other neurotransmitter peripheral and adult stem cells. They found that specifically inhibiting P2X7 receptors can rescue ATP-induced cell death, which may account for nerve Damage stem cell transplantation survival rate is low. The authors study may point out a new direction for the development of neurorestoratin combined with cell therapy and drug intervention. Relevant research point of view published in the "Chinese Journal of Nerve Regeneration Research (English version)" magazine in July 2014 No. 14 magazine.